Palladium Partners LLC Has $8.60 Million Position in UnitedHealth Group (UNH)

Palladium Partners LLC cut its position in UnitedHealth Group (NYSE:UNH) by 1.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,179 shares of the healthcare conglomerate’s stock after selling 399 shares during the quarter. Palladium Partners LLC’s holdings in UnitedHealth Group were worth $8,598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UNH. Exane Derivatives lifted its stake in UnitedHealth Group by 15,333.3% in the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock worth $102,000 after purchasing an additional 460 shares in the last quarter. Aevitas Wealth Management Inc. purchased a new stake in shares of UnitedHealth Group during the 4th quarter valued at $102,000. Pathstone Family Office LLC purchased a new stake in shares of UnitedHealth Group during the 4th quarter valued at $129,000. Trustcore Financial Services LLC purchased a new stake in shares of UnitedHealth Group during the 4th quarter valued at $133,000. Finally, Wealthcare Advisory Partners LLC raised its position in shares of UnitedHealth Group by 461.9% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 826 shares of the healthcare conglomerate’s stock valued at $162,000 after buying an additional 679 shares in the last quarter. Institutional investors and hedge funds own 85.10% of the company’s stock.

Several research firms have recently weighed in on UNH. Zacks Investment Research cut shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. Credit Suisse Group restated a “buy” rating on shares of UnitedHealth Group in a research report on Friday, March 9th. ValuEngine upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. JPMorgan Chase raised their price objective on shares of UnitedHealth Group to $266.00 and gave the company an “overweight” rating in a research report on Wednesday, April 18th. Finally, Oppenheimer raised their price objective on shares of UnitedHealth Group from $260.00 to $276.00 and gave the company an “outperform” rating in a research report on Wednesday, April 18th. Two research analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $253.70.

In other UnitedHealth Group news, Director Richard T. Burke sold 15,000 shares of the firm’s stock in a transaction on Monday, April 23rd. The shares were sold at an average price of $234.20, for a total value of $3,513,000.00. Following the sale, the director now owns 1,761,533 shares of the company’s stock, valued at approximately $412,551,028.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kenneth Irwin Shine sold 202 shares of the firm’s stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total transaction of $47,958.84. Following the completion of the sale, the director now directly owns 28,948 shares in the company, valued at approximately $6,872,834.16. The disclosure for this sale can be found here. In the last three months, insiders sold 72,019 shares of company stock worth $16,550,733. Insiders own 0.87% of the company’s stock.

UnitedHealth Group opened at $247.90 on Tuesday, MarketBeat reports. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.71 and a current ratio of 0.71. UnitedHealth Group has a 52 week low of $172.60 and a 52 week high of $250.79. The firm has a market cap of $235.09 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 1.41 and a beta of 0.75.

UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.91 by $0.13. The business had revenue of $55.19 billion for the quarter, compared to analyst estimates of $54.90 billion. UnitedHealth Group had a net margin of 5.41% and a return on equity of 22.06%. The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.37 EPS. research analysts expect that UnitedHealth Group will post 12.61 earnings per share for the current year.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply